PURPOSE: The purpose of this study was to demonstrate a novel protein-based magnetic resonance imaging (MRI) contrast agent that has the capability of targeting prostate cancer and which provides high-sensitivity MR imaging in tumor cells and mouse models. PROCEDURE: A fragment of gastrin-releasing peptide (GRP) was fused into a protein-based MRI contrast agent (ProCA1) at different regions. MR imaging was obtained in both tumor cells (PC3 and H441) and a tumor mouse model administrated with ProCA1.GRP. RESULTS: PC3 and DU145 cells treated with ProCA1.GRPs exhibited enhanced signal in MRI. Intratumoral injection of ProCA1.GRP in a PC3 tumor model displayed enhanced MRI signal. The contrast agent was retained in the PC3 tumor up to 48 h post-injection. CONCLUSIONS: Protein-based MRI contrast agent with tumor targeting modality can specifically target GRPR-positive prostate cancer. Intratumoral injection of the ProCA1 agent in the prostate cancer mouse model verified the targeting capability of ProCA1.GRP and showed a prolonged retention time in tumors.
PURPOSE: The purpose of this study was to demonstrate a novel protein-based magnetic resonance imaging (MRI) contrast agent that has the capability of targeting prostate cancer and which provides high-sensitivity MR imaging in tumor cells and mouse models. PROCEDURE: A fragment of gastrin-releasing peptide (GRP) was fused into a protein-based MRI contrast agent (ProCA1) at different regions. MR imaging was obtained in both tumor cells (PC3 and H441) and a tumormouse model administrated with ProCA1.GRP. RESULTS:PC3 and DU145 cells treated with ProCA1.GRPs exhibited enhanced signal in MRI. Intratumoral injection of ProCA1.GRP in a PC3tumor model displayed enhanced MRI signal. The contrast agent was retained in the PC3tumor up to 48 h post-injection. CONCLUSIONS: Protein-based MRI contrast agent with tumor targeting modality can specifically target GRPR-positive prostate cancer. Intratumoral injection of the ProCA1 agent in the prostate cancermouse model verified the targeting capability of ProCA1.GRP and showed a prolonged retention time in tumors.
Authors: D C Heimbrook; M E Boyer; V M Garsky; N L Balishin; D M Kiefer; A Oliff; M W Riemen Journal: J Biol Chem Date: 1988-05-25 Impact factor: 5.157
Authors: Mette L Johansen; Ying Gao; Melanie A Hutnick; Sonya E L Craig; Jonathan K Pokorski; Chris A Flask; Susann M Brady-Kalnay Journal: Anal Chem Date: 2017-05-22 Impact factor: 6.986
Authors: Avan Kader; Julia Brangsch; Jan O Kaufmann; Jing Zhao; Dilyana B Mangarova; Jana Moeckel; Lisa C Adams; Ingolf Sack; Matthias Taupitz; Bernd Hamm; Marcus R Makowski Journal: Biomedicines Date: 2020-12-22
Authors: Natalia V Pozdniakova; Oxana V Ryabaya; Alevtina S Semkina; Vsevolod A Skribitsky; Alexei B Shevelev Journal: Int J Mol Sci Date: 2022-03-18 Impact factor: 5.923